HARVARD BIOSCIENCE INC
For the period ended Mar 31, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 12, 2026
HBIO$9.26+1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| HARVARD BIOSCIENCE, INC. | ||
|---|---|---|
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | ||
| (Unaudited, in thousands) | ||
| Three Months Ended March 31, | ||
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss | $(3,424) | $(50,340) |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | ||
| Depreciation | 443 | 451 |
| Amortization of intangible assets | 907 | 1,204 |
| Goodwill impairment - Note 5 | - | 47,951 |
| Amortization of deferred financing costs | 446 | 131 |
| Stock-based compensation | 257 | 600 |
| Deferred income taxes and other | (85) | (523) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 1,406 | 1,438 |
| Inventories | (1,540) | 670 |
| Other assets | (392) | 29 |
| Accounts payable and other liabilities | 1,181 | 1,472 |
| Contract liabilities | 139 | (97) |
| Net cash (used in) provided by operating activities | (662) | 2,986 |
| Cash flows from investing activities: | ||
| Additions to property, plant and equipment | (426) | (513) |
| Capitalized software development costs | (194) | (170) |
| Net cash used in investing activities | (620) | (683) |
| Cash flows from financing activities: | ||
| Repayment of term debt | - | (1,000) |
| Payment of debt issuance costs | (129) | (129) |
| Proceeds from exercise of stock options and employee stock purchase plan | 150 | - |
| Taxes paid related to net share settlement of equity awards | (30) | (75) |
| Net cash used in financing activities | (9) | (1,204) |
| Effect of exchange rate changes on cash | (225) | 339 |
| (Decrease) increase in cash and cash equivalents | (1,516) | 1,438 |
| Cash and cash equivalents at beginning of period | 8,614 | 4,108 |
| Cash and cash equivalents at end of period | $7,098 | $5,546 |
| Supplemental disclosures of cash flow information: | ||
| Cash paid for interest | $1,280 | $799 |
| Cash paid for income taxes, net of refunds | $(5) | $2 |
**NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.